Tuberculosis - A multisystemic disease and antimicrobial resistance in Mycobacterium tuberculosis
Main Article Content
Abstract
Tuberculosis (TB) is the leading global cause of infectious disease death. Though all age groups are at risk but it highly effects adults in their most productive years. Tuberculosis is preventable and curable. There are several drugs that work against tuberculosis disease which target various aspects of Mycobacterium tuberculosis (causative agent of TB). Though some drugs (rifampicin, pyrazinamide) are much more effective but the situation gets worse by the presence of multi drug-resistant strain of Mycobacterium. Antimicrobial resistance occurs as a result of biological variations in drug uptake or substandard drugs. In the last two decades, multidrug-resistant strain of Mycobacterium tuberculosis has emerged as a threat to public health, stressing the need to develop new tuberculosis prevention and treatment strategies. Advances in many technologies such as Whole Genome Sequencing (WGS) technology use as a tool for rapid diagnosis and clinical management of TB. The introduction of new database such as Relational sequencing TB data platform may be helpful. In this review article, provide an update on advances in our understanding to new, existing drugs and repurposed agents, it will help devise better molecular diagnostics for more effective drug resistance tuberculosis (DR-TB) management enabling personalized treatment and will facilitate the development of new drugs.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Escribano I, Rodríguez J, Llorca B et al. (2007) Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy; 53: 397–401.
Fonseca J, Knight G, McHugh T. (2015). The complex evolution of antibiotic resistance in Mycobacterium tuberculosis. Int J Infect Dis; 32: 94–100.
Gegia M, Winters N, Benedetti A et al. (2017) Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis; 17: 223–34.
Gillespie SH. (2002) Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother; 46: 267–74
Ioerger TR, Koo S, No E-G et al. (2009) Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS One; 4: e7778.
Konno K, Feldmann FM, McDermott W. (1967) Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis; 95: 461–9.
Manjunatha UH, Boshoff H, Dowd CS et al. (2006). Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA; 103: 431–6.
Palomino JC, Martin A. (2014) Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel); 3: 317–40.
Rengarajan J, Sassetti CM, Naroditskaya V et al. (2004) The folate pathway is a target for resistance to the drug para‐aminosalicylic acid (PAS) in mycobacteria. Mol Microbiol; 53: 275–82.
Safi H, Sayers B, Hazbón MH et al. (2008) Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother; 52: 2027–34.
Singh R, Manjunatha U, Boshoff HI et al. (2008) PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science; 322: 1392–5.
Sreevatsan S, Stockbauer KE, Pan X et al. (1997) Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother; 41: 1677–81.
Takayama K, Kilburn JO. (1989) Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother; 33: 1493.
Traore H, Fissette K, Bastian I et al. (2000) Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance [Technical Note]. Int J Tuberculosis Lung Dis; 4: 481–4.
Vilchèze C, Av-Gay Y et al. (2008) Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis. Mol Microbiol; 69: 1316–29.
Zhao F, Wang X-D, Erber LN et al. (2014) Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother; 58: 1479–87.